Bacteriophages: Clinical significance and application prospects

Abstract

A review of the literature data covering topical issues of the use of bacteriophages in clinical practice is presented. Traditionally, phage therapy is based on the use of natural phages for the lysis of bacteria at the infection site. Despite some limitations, it has significant advantages over antibiotic therapy. The use of biotechnological methods currently makes it possible to eliminate the disadvantages of phage therapy by creating recombinant drugs and, in the future, expand its capabilities through the use of lytic phage proteins and their modified derivatives. Currently, bacteriophages are used not only for the treatment of infections but also for prevention and diagnosis (phagotyping to identify the source of infection). Bacteriophages are also used in genetic engineering as vectors for transferring DNA sections. Few side effects have been described about bacteriophages. Particularly, they do not negatively affect the intestinal microbiota, and compared with antibiotics, they are much less likely to be associated with allergic reactions. Moreover, existing randomized clinical trials, which are the gold standard of clinical trials, in phage therapy are extremely insufficient, which dictates the need to concentrate the efforts of all stakeholders in this direction.

Keywords

bacteriophages / bacteria / antibiotics / antibiotic resistance

References

[1] Danilov AI, Litvinov AV. The start of the era of antimicrobial chemotherapy. Clinical Microbiology and Antimicrobial Chemotherapy. 2010;12(2):163–169.

[2] Данилов А.И., Литвинов А.В. Начало эры антимикробной химиотерапии // Клиническая микробиология и антимикробная химиотерапия. 2010. Т. 12, № 2. С. 163–169.

[3] Artyukh TV, Sheybak VM, Ostrovskaya OB. Changing the sensitivity of gram-positive microorganisms to doxycycline in the presence of zinc aspartate and tryptophan. Vestnik SGMA. 2023;22(1):34–41. DOI: 10.37903/vsgma.2023.1.5

[4] Артюх Т.В., Шейбак В.М., Островская О.Б. Изменение чувствительности грамположительных микроорганизмов к доксициклину в присутствии цинка аспартата и триптофана // Вестник СГМА. 2023. Т. 22, № 1. С. 34–41. DOI: 10.37903/vsgma.2023.1.5

[5] Yakovleva EE, Beleckaya YuA, Yakovlev AV, Shabanov PD. Kl. pneumonia antibiotic resistance and modern approaches to the treatment of nosocomial infections in newborns. Vestnik SGMA. 2022;20(2):54–60. DOI: 10.37903/vsgma.2022.2.8

[6] Яковлева Е.Е., Белецкая Ю.А., Яковлев А.В., Шабанов П.Д. Антибактериальная резистентность Kl. pneumonia и современные подходы к терапии нозокомиальных инфекций у новорожденных // Вестник СГМА. 2022. Т. 20, № 2. С. 54–60. DOI: 10.37903/vsgma.2022.2.8

[7] Teresa GG. Antibiotic resistance: Time of synthesis in a post-genomic age. Comput Struct Biotechnol J. 2021;19:3110–3124.

[8] Teresa G.G. Antibiotic resistance: Time of synthesis in a post-genomic age // Comput Struct Biotechnol J. 2021. Vol. 19. P. 3110–3124.

[9] Danilov AI, Zharkova LP. Antibiotic resistance: arguments and facts. Clinical Pharmacology and Therapy. 2017;26(5):6–9. (In Russ.)

[10] Данилов А.И., Жаркова Л.П. Антибиотикорезистентность: аргументы и факты // Клиническая фармакология и терапия. 2017. Т. 26, № 5. С. 6–9.

[11] Fominyh SG, Shukil’ LV, Razumovskaja AA, et al. Pharmacoeconomical and pharmacoepidemiological methods in evaluating the effectiveness of cephalosporins protected by beta-lactamase inhibitors. Vestnik SGMA. 2023;21(2):28–33. DOI: 10.37903/vsgma.2023.2.4

[12] Фоминых С.Г., Шукиль Л.В., Разумовская А.А., и др. Фармакоэкономические и фармакоэпидемиологические методы в оценке эффективности цефалоспоринов, защищенных ингибиторами β-лактомаз // Вестник СГМА. 2023. Т. 21, № 2. С. 28–33. DOI: 10.37903/vsgma.2023.2.4

[13] Bellini C, Troilet N. Antibiotic resistance: situation in Europe and Switzerland, and impact for the physician. Rev Med Suisse. 2016;12(534):1699–1702.

[14] Bellini C., Troilet N. Antibiotic resistance: situation in Europe and Switzerland, and impact for the physician // Rev Med Suisse. 2016. Vol. 12, No. 534. P. 1699–1702.

[15] Golubovskaja OA. Antibiotic resistance and international actions of its overcoming. Clinical Infectology and Parasitology. 2015;(1(12)):6–11.

[16] Голубовская О.А. Проблема антибиотикорезистентности и международные усилия по ее преодолению // Клиническая инфектология и паразитология. 2015. № 1(12). С. 6–11.

[17] Chanishvili N. Phage therapy history from Twort and d’Herelle through Soviet experience to current approaches. Adv Virus Res. 2012;83:3–40. DOI: 10.1016/b978-0-12-394438-2.00001-3

[18] Chanishvili N. Phage therapy history from Twort and d’Herelle through Soviet experience to current approaches // Adv Virus Res. 2012. Vol. 83. P. 3–40. DOI: 10.1016/b978-0-12-394438-2.00001-3

[19] Hodyra-Stefaniak K, Miernikiewicz P, Drapała J, et al. Mammalian Host-Versus-Phage immune response determines phage fate in vivo. Sci Rep. 2015;5:14802. DOI: 10.1038/srep14802

[20] Hodyra-Stefaniak K., Miernikiewicz P., Drapała J., et al. Mammalian Host-Versus-Phage immune response determines phage fate in vivo // Sci Rep. 2015. Vol. 5. P. 14802. DOI: 10.1038/srep14802

[21] Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017;8(3):162–173. DOI: 10.4292/wjgpt.v8.i3.162

[22] Lin D.M., Koskella B., Lin H.C. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance // World J Gastrointest Pharmacol Ther. 2017. Vol. 8, No. 3. P. 162–173. DOI: 10.4292/wjgpt.v8.i3.162

[23] Akimkin VG, Darbeeva OS, Kolkov VF. Historical and modern aspects of bacteriophages application: experience and prospects. Journal of Clinical Practice. 2010;1(4):48–54. DOI: 10.17816/clinpract1448-54

[24] Акимкин В.Г., Дарбеева О.С., Колков В.Ф. Бактериофаги: исторические и современные аспекты их применения: опыт и перспективы // Клиническая практика. 2010. Т. 1, № 4. С. 48–54. DOI: 10.17816/clinpract1448-54

[25] Perepanova TS, Kazachenko AV, Hazan PL, et al. Bacteriophage therapy: back to the future. Clinical Microbiology and Antimicrobial Chemotherapy. 2021;23(1):55–64. DOI:10.36488/cmac.2021.1.55-64

[26] Перепанова Т.С., Казаченко А.В., Хазан П.Л., Малова Ю.А. Терапевтическое применение бактериофагов: назад в будущее // Клиническая микробиология и антимикробная химиотерапия. 2021. Т. 23, № 1. С. 55–64. DOI: 10.36488/cmac.2021.1.55-64

[27] Cui Z, Guo X, Feng T, Li L. Exploring the whole standard operating procedure for phage therapy in clinical practice. J Transl Med. 2019;17(1):373. DOI: 10.1186/s12967-019-2120-z

[28] Cui Z., Guo X., Feng T., Li L. Exploring the whole standard operating procedure for phage therapy in clinical practice // J Transl Med. 2019. Vol. 17, No. 1. P. 373. DOI: 10.1186/s12967-019-2120-z

[29] Crawford DH. Viruses: A very short introduction. Oxford University Press; 1st edition. 2011. 156 p.

[30] Crawford D.H. Viruses: A very short introduction. Oxford University Press; 1st edition. 2011. 156 p.

[31] Bykov AS, Bykov SA. Bacteriophages and their clinical significance. Farmateka. 2011;5:67–72.

[32] Быков А.С., Быков С.А. Бактериофаги и их клиническое значение // Фарматека. 2011. № 5. С. 67–72.

[33] Rakhuba DV, Kolomiets EI, Dey ES, Novik GI. Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell. Pol J Microbiol. 2010;59:145–155.

[34] Rakhuba D.V., Kolomiets E.I., Dey E.S., Novik G.I. Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell // Pol J Microbiol. 2010. Vol. 59. P. 145–155.

[35] Hajrullin IN, Pozdeev OK, Shajmardanov RSh. Efficiency of using specific bacteriophages in the treatment and prophylaxis of surgical postoperative infection. Kazan Medical Journal. 2002;83(4):258–261.

[36] Хайруллин И.Н., Поздеев О.К., Шаймарданов Р.Ш. Эффективность применения специфических бактериофагов в лечении и профилактике хирургических послеоперационных инфекций // Казанский медицинский журнал. 2002. Т. 83, № 4. С. 258–261.

[37] Lazareva EB. Bacteriophages for treatment and prevention of infectious diseases. Antibiotics and Chemotherapy. 2003;48(1):36–40. (In Russ.)

[38] Лазарева Е.Б. Бактериофаги для лечения и профилактики инфекционных заболеваний // Антибиотики и химиотерапия. 2003. Т. 48, № 1. С. 36–40.

[39] Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch Immunol Ther Exp (Warsz). 1987;35:569–583.

[40] Slopek S., Weber-Dabrowska B., Dabrowski M., Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986 // Arch Immunol Ther Exp (Warsz). 1987. Vol. 35. P. 569–583.

[41] Lang G, Kehr P, Mathevon H, et al. Bacteriophage therapy of septic complications of orthopaedic surgery (author’s transl.) Rev Chir Orthop Reparatrice Appar Mot. 1979;65:33–37.

[42] Lang G., Kehr P., Mathevon H., et al. Bacteriophage therapy of septic complications of orthopaedic surgery (author’s transl) // Rev Chir Orthop Reparatrice Appar Mot. 1979. Vol. 65. P. 33–37.

[43] Perepanova TS, Darbeeva OS, Kotljarova GA, et al. The efficacy of bacteriophage preparations in treating inflammatory urologic diseases. Urologiya i Nefrologiya. 1995;(5):14–17.

[44] Перепанова Т.С., Дарбеева О.С., Котлярова Г.А., и др. Эффективность препаратов бактериофагов при лечении воспалительных урологических заболеваний // Урология и нефрология. 1995. № 5. С. 14–17.

[45] Anikina TA, Ryazanova SH, Sergeeva EN. Freshly isolated strains of pathogens — the most important component of production of adapted therapeutic and prophylactic bacteriophages. “ImBio”. Nizhny Novgorod: Vaccinology; 2006. 3 p. (In Russ.)

[46] Аникина Т.А., Рязанова С.Х., Сергеева Е.Н. Свежевыделенные штаммы возбудителей-важнейший компонент производства адаптированных лечебно-профилактических бактериофагов. «ИмБио». Нижний Новгород: Вакцинология, 2006. 3 c.

[47] Maciejewska B, Olszak T, Drulis-Kawa Z. Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application? Appl Microbiol Biotechnol. 2018;102(6):2563–2581. DOI: 10.1007/s00253-018-8811-1

[48] Maciejewska B., Olszak T., Drulis-Kawa Z. Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application? // Appl Microbiol Biotechnol. 2018. Vol. 102, No. 6. P. 2563–2581. DOI: 10.1007/s00253-018-8811-1

[49] Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotechnol. 2010;11(1):28–47. DOI: 10.2174/138920110790725410

[50] Abedon S.T., Thomas-Abedon C. Phage therapy pharmacology // Curr Pharm Biotechnol. 2010. Vol. 11, No. 1. P. 28–47. DOI: 10.2174/138920110790725410

[51] Dufour N, Delattre R, Ricard JD, Debarbieux L. The lysis of pathogenic Escherichia coli by bacteriophages releases less endotoxin than by betalactams. Clin Infect Dis. 2017;64(11):1582–1588. DOI: 10.1093/cid/cix184

[52] Dufour N., Delattre R., Ricard J.D., Debarbieux L. The lysis of pathogenic Escherichia coli by bacteriophages releases less endotoxin than by betalactams // Clin Infect Dis. 2017. Vol. 64, No. 11. P. 1582–1588. DOI: 10.1093/cid/cix184

RIGHTS & PERMISSIONS

ECO-vector